Drug labeling must reflect origin of active ingredient -- U.S. Customs NAFTA rule.

DRUG LABELING MUST REFLECT BULK PHARMACEUTICAL COUNTRY OF ORIGIN under a recent Customs Service decision, the Washington, D.C. law firm McKenna & Cuneo warns manufacturers in a June 28 client advisory. "Drug manufacturers and distributors of pharmaceutical products made with imported active ingredients should re-examine their country-of- origin labeling as a result of a position statement of the U.S. Customs Service" issued June 6 to implement the North American Free Trade Agreement, McKenna & Cuneo states.